MX2019002579A - Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. - Google Patents
Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.Info
- Publication number
- MX2019002579A MX2019002579A MX2019002579A MX2019002579A MX2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A
- Authority
- MX
- Mexico
- Prior art keywords
- nafld
- nash
- ald
- gamma
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pediatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383895P | 2016-09-06 | 2016-09-06 | |
| US201662410133P | 2016-10-19 | 2016-10-19 | |
| PCT/US2017/050317 WO2018048932A1 (en) | 2016-09-06 | 2017-09-06 | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002579A true MX2019002579A (es) | 2020-02-05 |
Family
ID=61562136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002579A MX2019002579A (es) | 2016-09-06 | 2017-09-06 | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180153827A1 (enExample) |
| EP (1) | EP3510014A4 (enExample) |
| JP (3) | JP7189127B2 (enExample) |
| CN (2) | CN110177771B (enExample) |
| AU (1) | AU2017324935B2 (enExample) |
| CA (1) | CA3035897A1 (enExample) |
| MX (1) | MX2019002579A (enExample) |
| WO (1) | WO2018048932A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201074A1 (en) * | 2017-04-27 | 2018-11-01 | Vanderbilt University | Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers |
| MX2020002441A (es) * | 2017-09-05 | 2020-09-03 | Mti Biotech Inc | Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado. |
| EP3914359B1 (en) * | 2019-01-25 | 2025-03-26 | MTI Biotech, Inc. | Triphenylphosphonium-tethered salicylamine derivatives |
| CN114344448A (zh) * | 2022-01-20 | 2022-04-15 | 广西医科大学第一附属医院 | Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023063A2 (en) * | 1998-10-22 | 2000-04-27 | University Of South Carolina | Methods for inhibiting diabetic complications |
| CA2369560C (en) * | 1999-04-27 | 2011-02-01 | Makoto Nakamuta | Agent for prophylaxis and treatment of liver disease |
| CN1628650A (zh) * | 2003-12-19 | 2005-06-22 | 刘力 | 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法 |
| US8822542B2 (en) * | 2004-10-20 | 2014-09-02 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| WO2008070778A2 (en) * | 2006-12-06 | 2008-06-12 | Nephrogenex Inc. | Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease |
| EP2281557A4 (en) | 2008-04-29 | 2011-08-31 | Hanall Biopharma Co Ltd | PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT |
| KR20140050661A (ko) * | 2011-07-12 | 2014-04-29 | 벤더르빌트 유니버시티 | 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 |
| US20150087660A1 (en) * | 2012-05-10 | 2015-03-26 | Mahesh Kandula | Compositions and methods for the treatment of chronic diseases and inflammatory disorders |
| US20150265584A1 (en) * | 2014-03-18 | 2015-09-24 | Vanderbilt University | Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna |
| JP2017537149A (ja) * | 2014-11-11 | 2017-12-14 | ヴァンダービルト ユニバーシティー | 急性腎傷害を制限するための方法 |
| WO2017033119A1 (en) * | 2015-08-25 | 2017-03-02 | Rao M Surya | Compositions and methods for the treatment of liver metabolic diseases |
| US20210023032A1 (en) * | 2017-09-05 | 2021-01-28 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
| MX2020002441A (es) * | 2017-09-05 | 2020-09-03 | Mti Biotech Inc | Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado. |
-
2017
- 2017-09-06 MX MX2019002579A patent/MX2019002579A/es unknown
- 2017-09-06 CA CA3035897A patent/CA3035897A1/en active Pending
- 2017-09-06 EP EP17849471.2A patent/EP3510014A4/en active Pending
- 2017-09-06 AU AU2017324935A patent/AU2017324935B2/en active Active
- 2017-09-06 CN CN201780064767.2A patent/CN110177771B/zh active Active
- 2017-09-06 CN CN202211453642.8A patent/CN119345198A/zh active Pending
- 2017-09-06 WO PCT/US2017/050317 patent/WO2018048932A1/en not_active Ceased
- 2017-09-06 US US15/697,193 patent/US20180153827A1/en not_active Abandoned
- 2017-09-06 JP JP2019512804A patent/JP7189127B2/ja active Active
-
2022
- 2022-12-01 JP JP2022192727A patent/JP2023022236A/ja active Pending
- 2022-12-08 US US18/077,832 patent/US12383515B2/en active Active
-
2024
- 2024-12-06 JP JP2024213390A patent/JP2025032245A/ja active Pending
-
2025
- 2025-08-07 US US19/294,041 patent/US20250360094A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3510014A4 (en) | 2020-05-20 |
| AU2017324935B2 (en) | 2021-10-21 |
| AU2017324935A1 (en) | 2019-03-28 |
| CN110177771B (zh) | 2022-12-13 |
| CA3035897A1 (en) | 2018-03-15 |
| US20180153827A1 (en) | 2018-06-07 |
| JP7189127B2 (ja) | 2022-12-13 |
| JP2023022236A (ja) | 2023-02-14 |
| US20230181494A1 (en) | 2023-06-15 |
| WO2018048932A1 (en) | 2018-03-15 |
| JP2019526598A (ja) | 2019-09-19 |
| CN110177771A (zh) | 2019-08-27 |
| US12383515B2 (en) | 2025-08-12 |
| EP3510014A1 (en) | 2019-07-17 |
| CN119345198A (zh) | 2025-01-24 |
| BR112019004404A2 (pt) | 2019-05-28 |
| US20250360094A1 (en) | 2025-11-27 |
| JP2025032245A (ja) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010269A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| GEP201706663B (en) | Novel composition for nonalcoholic fatty liver disease (nafld | |
| ZA201801852B (en) | Anti¿pd¿1 antibodies and compositions | |
| MX2017009532A (es) | Uso de acidos grasos de cadena corta en prevencion de cancer. | |
| EA201791982A1 (ru) | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии | |
| EA201692050A1 (ru) | Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
| MX2019005082A (es) | Composiciones que comprenden 15-ohepa y metodos para usar las mismas. | |
| JO3686B1 (ar) | جلوكان ومركبات مساعِدات glp-1 مشتركة | |
| PH12016501441B1 (en) | Chimeric alkaline phosphatase-like proteins | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| NZ776661A (en) | Rnai constructs for inhibiting pnpla3 expression | |
| PH12018500659A1 (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| IL284345A (en) | Preparations and methods for the treatment of non-alcoholic fatty liver diseases | |
| MX2021003156A (es) | Tratamiento para la enfermedad del higado graso no alcoholico. | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| MX2021005245A (es) | Composiciones de oligosacaridos y metodos de uso de las mismas. | |
| MX2012012095A (es) | Analogos de tiazolidinadiona. | |
| PH12017550090B1 (en) | Composition for improving or preventing nonalcoholic fatty liver | |
| MX2021001393A (es) | Composiciones para el tratamiento de la enfermedad de injerto contra huesped. | |
| PH12017501693A1 (en) | Compositions for the treatment of kidney and/or liver diseases | |
| EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии |